Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy.

Čtvrtlík F, Koranda P, Schovánek J, Škarda J, Hartmann I, Tüdös Z.

Exp Ther Med. 2018 Apr;15(4):3151-3160. doi: 10.3892/etm.2018.5871. Epub 2018 Feb 14.

2.

Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.

Khatami F, Tavangar SM.

Iran J Pathol. 2017 Summer;12(3):313-322. Epub 2017 Jul 1. Review.

3.

Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma.

Smestad J, Hamidi O, Wang L, Holte MN, Khazal FA, Erber L, Chen Y, Maher LJ 3rd.

Oncotarget. 2017 Dec 22;9(5):6109-6127. doi: 10.18632/oncotarget.23639. eCollection 2018 Jan 19.

4.

Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Eisenhofer G, Klink B, Richter S, Lenders JW, Robledo M.

Clin Biochem Rev. 2017 Apr;38(2):69-100. Review.

5.

ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma.

Wang D, Song L, Wang L, Zhao L, Xiang B, Li Y, Shan B, Liu J.

Oncotarget. 2017 Sep 21;8(49):86325-86338. doi: 10.18632/oncotarget.21149. eCollection 2017 Oct 17.

6.

New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Crona J, Taïeb D, Pacak K.

Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062.

PMID:
28938417
7.

Molecular and phenotypic evaluation of a novel germline TMEM127 mutation with an uncommon clinical presentation.

Deng Y, Flores SK, Cheng Z, Qin Y, Schwartz RC, Malchoff C, Dahia PLM.

Endocr Relat Cancer. 2017 Nov;24(11):L79-L82. doi: 10.1530/ERC-17-0359. Epub 2017 Aug 30. No abstract available.

PMID:
28855235
8.

Review of Pediatric Pheochromocytoma and Paraganglioma.

Bholah R, Bunchman TE.

Front Pediatr. 2017 Jul 13;5:155. doi: 10.3389/fped.2017.00155. eCollection 2017. Review.

9.

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.

Hamidi O, Young WF Jr, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305. doi: 10.1210/jc.2017-00992.

PMID:
28605453
10.

SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity.

Casey RT, Ascher DB, Rattenberry E, Izatt L, Andrews KA, Simpson HL, Challis B, Park SM, Bulusu VR, Lalloo F, Pires DEV, West H, Clark GR, Smith PS, Whitworth J, Papathomas TG, Taniere P, Savisaar R, Hurst LD, Woodward ER, Maher ER.

Mol Genet Genomic Med. 2017 Mar 2;5(3):237-250. doi: 10.1002/mgg3.279. eCollection 2017 May.

11.

Mitochondrial Deficiencies in the Predisposition to Paraganglioma.

Lussey-Lepoutre C, Buffet A, Gimenez-Roqueplo AP, Favier J.

Metabolites. 2017 May 4;7(2). pii: E17. doi: 10.3390/metabo7020017. Review.

12.

Novel germline variant of TMEM127 gene in a patient with familial pheochromocytoma.

Saitoh K, Yonemoto T, Usui T, Takekoshi K, Suzuki M, Nakashima Y, Yoshimura K, Kosugi R, Ogawa T, Inoue T.

Endocrinol Diabetes Metab Case Rep. 2017 Apr 6;2017. pii: 17-0014. doi: 10.1530/EDM-17-0014. eCollection 2017.

13.

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.

Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group.

JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223.

14.

Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations.

Backman S, Maharjan R, Falk-Delgado A, Crona J, Cupisti K, Stålberg P, Hellman P, Björklund P.

Sci Rep. 2017 Mar 22;7:44943. doi: 10.1038/srep44943.

15.

Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Osinga TE, Links TP, Dullaart RPF, Pacak K, van der Horst-Schrivers ANA, Kerstens MN, Kema IP.

FASEB J. 2017 Jun;31(6):2226-2240. doi: 10.1096/fj.201601131R. Epub 2017 Mar 6. Review.

PMID:
28264974
16.

Molecular markers of paragangliomas/pheochromocytomas.

Zhikrivetskaya SO, Snezhkina AV, Zaretsky AR, Alekseev BY, Pokrovsky AV, Golovyuk AL, Melnikova NV, Stepanov OA, Kalinin DV, Moskalev AA, Krasnov GS, Dmitriev AA, Kudryavtseva AV.

Oncotarget. 2017 Apr 11;8(15):25756-25782. doi: 10.18632/oncotarget.15201. Review.

17.

Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients.

Bennedbæk M, Rossing M, Rasmussen ÅK, Gerdes AM, Skytte AB, Jensen UB, Nielsen FC, Hansen TVO.

Hered Cancer Clin Pract. 2016 Jun 8;14:13. doi: 10.1186/s13053-016-0053-6. eCollection 2016.

18.

Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.

Lee SE, Oh E, Lee B, Kim YJ, Oh DY, Jung K, Choi JS, Kim J, Kim SJ, Yang JW, An J, Oh YL, Choi YL.

Oncotarget. 2016 Apr 26;7(17):24141-53. doi: 10.18632/oncotarget.8234.

19.

The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Robbins HL, Hague A.

Front Endocrinol (Lausanne). 2016 Jan 11;6:188. doi: 10.3389/fendo.2015.00188. eCollection 2015. Review.

20.

Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.

Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, Prasad ML, Ocal IT, Rao S, Aronin N, Barontini M, Bruder J, Reddick RL, Chen Y, Aguiar RC, Dahia PL.

Clin Cancer Res. 2016 May 1;22(9):2301-10. doi: 10.1158/1078-0432.CCR-15-1841. Epub 2015 Dec 23.

Supplemental Content

Support Center